PALISADE BIO, INC.
For the period ended Jun 30, 2025. Filed Aug 11, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 11, 2025
PALI$1.13-5.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
nts of Cash Flows (Unaudited)
(in thousands)
| Six Months Ended June 30, | ||
|---|---|---|
| 2025 | 2024 | |
| Net loss | $(5,014) | $(7,607) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 2 | 2 |
| Non-cash operating lease expense | 62 | 56 |
| Recurring fair value measurements of liabilities | (9) | 5 |
| Issuance of common stock to vendors | — | 73 |
| Write-off of deferred equity issuance costs | 75 | — |
| Loss on disposal of property and equipment | — | 4 |
| Stock-based compensation and related charges | 138 | 480 |
| Changes in operating assets and liabilities: | ||
| Prepaid and other current assets and other noncurrent assets | (18) | 349 |
| Accounts payable and accrued liabilities | 1,210 | 506 |
| Accrued compensation and benefits | (530) | (490) |
| Operating lease liabilities | (66) | (57) |
| Net cash used in operating activities | (4,150) | (6,679) |
| Cash flows from financing activities: | ||
| Payments on insurance financing debt | (80) | (158) |
| Proceeds from issuance of common stock and warrants | — | 4,000 |
| Proceeds from the exercise of warrants | 1 | 2,503 |
| Payment of warrant inducement issuance costs | — | (343) |
| Payment of equity issuance costs | (178) | (388) |
| Proceeds from issuance of common stock under Employee Stock Purchase Plan | 3 | 11 |
| Shares withheld for payment of employee withholding tax liability | — | (25) |
| Net cash (used in) provided by financing activities | (254) | 5,600 |
| Net decrease in cash, cash equivalents and restricted cash | (4,404) | (1,079) |
| Cash, cash equivalents and restricted cash, beginning of period | 9,847 | 12,458 |
| Cash, cash equivalents and restricted cash, end of period | $5,443 | $11,379 |
| Reconciliation of cash, cash equivalents and restricted cash to the balance sheets: | ||
| Cash and cash equivalents | $5,417 | $11,353 |
| Restricted cash | 26 | 26 |
| Total cash, cash equivalents and restricted cash | $5,443 | $11,379 |
| Supplemental disclosures of cash flow information: | ||
| Interest paid | $1 | $2 |
| Supplemental disclosures of non-cash investing and financing activities: | ||
| Warrant inducement and equity issuance costs included in accounts payable and accrued liabilities | $— | $68 |
| Transaction costs included in accounts payable and accrued liabilities | — | — |
| Fair value of warrants issued to solicitation agent | — | 94 |
| Fair value of warrants issued to placement agent | — | 249 |
| Deferred equity issuance costs recognized as a reduction in additional paid-in capital from financing activities | — | 37 |
| Insurance financing debt included in prepaid and other current assets and other noncurrent assets | 312 | 346 |
| Incremental fair value of modified warrants (Note 5) | — | 1,975 |
PALISADE BIO, INC.
NOTES TO CONDENSED CONSO
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.